Actively Recruiting
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Led by Ascendis Pharma A/S · Updated on 2026-03-02
50
Participants Needed
1
Research Sites
514 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
CONDITIONS
Official Title
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 15 to 50 years
- Exposure to at least one dose of YORVIPATH within 15 days prior to conception or during pregnancy
- Written informed consent, verbal consent, or eConsent provided; for minors, assent from the pregnant adolescent and consent from parent or legal guardian obtained
You will not qualify if you...
- Pregnancies where only the male partner was exposed to at least one dose of YORVIPATH
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ascendis Investigational Site
Morgantown, West Virginia, United States, 26508
Actively Recruiting
Research Team
Y
Yorvipath Pregnancy Inquiries
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here